Pricing Log in Create free account

Hemab Therapeutics Holdings, Inc. (COAG) vs Immunome, Inc. (IMNM)

Hemab Therapeutics Holdings, Inc. and Immunome, Inc. are both Biotechnology companies. Hemab Therapeutics Holdings, Inc. and Immunome, Inc. are of similar size ($2.1B and $2.1B). Across the 7 metrics below, Hemab Therapeutics Holdings, Inc. leads on 6 and Immunome, Inc. on 1.

Valuation

Metric COAG IMNM Biotechnology median
P/E n/m n/m 10.60
P/S n/m 167.81 9.40
P/B 3.22 4.02 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 126.54 9.02
Earnings yield (110.83%) (13.57%) (32.88%)
Free cash flow yield (4.97%) (10.37%) (23.13%)

Profitability

Metric COAG IMNM Biotechnology median
Gross margin — 100.00% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% (64.03%) (51.96%)
Return on assets (31.79%) (59.03%) (46.06%)
Return on invested capital 0.00% (3,322.99%) 0.00%

Growth

Metric COAG IMNM Biotechnology median
Revenue growth (TTM) — 16.74% 6.76%
EPS growth (last fiscal year) — 51.40% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric COAG IMNM Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 35.85 15.08 4.97
Net debt to EBITDA — 2.92 1.01

Dividend

Metric COAG IMNM Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric COAG IMNM Biotechnology median
Market cap 2.13b 2.11b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack